News

Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors

News 23.03.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and...

read more

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

News 20.03.2026 ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the presentation of new clinical data from the global Phase 2 clinical trial (AP-101-02) evaluating the company’s lead program, AP-101, in patients with ALS. AP-101...

read more

ILMAC Lausanne

Events, External events
Event date: 23.09.2026 23 – 24 September 2026 Beaulieu Lausanne The largest event for the chemical and life sciences industry in French-speaking Switzerland. More information: https://www.ilmac.ch/   Informationen Startups:  https://www.ilmac.ch/en/lausanne/exhibit/on-site-participation/#Startup-Area Checklist  https://www.ilmac.ch/en/lausanne/visit/checklist/ Highlights 2026:  https://www.ilmac.ch/en/lausanne/highlights/ Aftermovie 2024: https://youtu.be/zWN_RyElHLE?si=TsUBLYmVg-KEBGia Impressionen Ilmac Lausanne: https://mam.mch-group.com/share/152C1474-0971-456E-AFFD17A2F7BF7C27/

read more

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes

News 19.03.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold an oral presentation outlining new preclinical...

read more